Background Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with poor
prognosis and limited treatment options after progression on platinum-containing …

Background: The programmed death receptor 1 (PD-1) pathway is implicated in evasion of
the antitumor immune response. Pembrolizumab is a potent, highly selective humanized …

Methods PEMMELA was a prospective single-center, single-arm, open-label, investigator-
initiated phase 2 trial of pembrolizumab (200 mg once every three weeks intravenously) plus …

Introduction There is no approved second-line treatment for malignant pleural mesothelioma
(MPM). On the basis of promising early results, pembrolizumab was used off-label in …

Background Malignant pleural mesothelioma is a highly aggressive cancer with poor
prognosis and few treatment options following progression on platinum-containing …

Background: Available 2nd line chemotherapies for relapsed malignant pleural
mesothelioma (MPM) have limited activity. Results from early clinical trials-including the …

Background Malignant pleural mesothelioma (MPM) is a rare and highly aggressive
malignancy with poor prognosis and limited treatment options beyond progression after …

Methods Adult patients with previously untreated, unresectable, histologically confirmed
MPM and ECOG performance status 0–1 were randomized (1: 1; stratified by histology …

Background Pembrolizumab showed significant activity in PD-L1+ MM in a phase IB study
(Alley, 2015). We are conducting a phase II trial (NCT02399371) of pembrolizumab in …

Background We conducted a phase II trial to assess the activity of pembrolizumab in a non-
selected population of mesothelioma patients and determine a PD-L1 expression threshold …